Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control
© The Author(s) 2021..
Dipeptidyl peptidase (DPP)-4 inhibitors are oral anti-diabetic medications that block the activity of the ubiquitous enzyme DPP-4. Inhibition of this enzyme increases the level of circulating active glucagon-like peptide (GLP)-1 secreted from L-cells in the small intestine. GLP-1 increases the glucose level, dependent on insulin secretion from pancreatic β-cells; it also decreases the abnormally increased level of glucagon, eventually decreasing the blood glucose level in patients with type 2 diabetes. DPP-4 is involved in many physiological processes other than the degradation of GLP-1. Therefore, the inhibition of DPP-4 may have numerous effects beyond glucose control. In this article, we review the pleiotropic effects of DPP-4 inhibitors beyond glucose control, including their strong beneficial effects on the stress induced accelerated senescence of vascular cells, and the possible clinical implications of these effects.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Clinical medicine insights. Endocrinology and diabetes - 14(2021) vom: 12., Seite 11795514211051698 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kang, Seon Mee [VerfasserIn] |
---|
Links: |
---|
Themen: |
DPP-4 inhibitors |
---|
Anmerkungen: |
Date Revised 05.11.2021 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1177/11795514211051698 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM332712184 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM332712184 | ||
003 | DE-627 | ||
005 | 20231225220128.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1177/11795514211051698 |2 doi | |
028 | 5 | 2 | |a pubmed24n1108.xml |
035 | |a (DE-627)NLM332712184 | ||
035 | |a (NLM)34733107 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Kang, Seon Mee |e verfasserin |4 aut | |
245 | 1 | 0 | |a Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 05.11.2021 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a © The Author(s) 2021. | ||
520 | |a Dipeptidyl peptidase (DPP)-4 inhibitors are oral anti-diabetic medications that block the activity of the ubiquitous enzyme DPP-4. Inhibition of this enzyme increases the level of circulating active glucagon-like peptide (GLP)-1 secreted from L-cells in the small intestine. GLP-1 increases the glucose level, dependent on insulin secretion from pancreatic β-cells; it also decreases the abnormally increased level of glucagon, eventually decreasing the blood glucose level in patients with type 2 diabetes. DPP-4 is involved in many physiological processes other than the degradation of GLP-1. Therefore, the inhibition of DPP-4 may have numerous effects beyond glucose control. In this article, we review the pleiotropic effects of DPP-4 inhibitors beyond glucose control, including their strong beneficial effects on the stress induced accelerated senescence of vascular cells, and the possible clinical implications of these effects | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a DPP-4 inhibitors | |
650 | 4 | |a pleiotropic effects | |
650 | 4 | |a senescence | |
650 | 4 | |a vascular cell | |
700 | 1 | |a Park, Jeong Hyun |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical medicine insights. Endocrinology and diabetes |d 2010 |g 14(2021) vom: 12., Seite 11795514211051698 |w (DE-627)NLM220114846 |x 1179-5514 |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2021 |g day:12 |g pages:11795514211051698 |
856 | 4 | 0 | |u http://dx.doi.org/10.1177/11795514211051698 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 14 |j 2021 |b 12 |h 11795514211051698 |